AHCO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-11-03

• In June 2026, management approved a plan aimed at reducing costs, streamlining operations, and optimizing resources, which included headcount reductions and the wind down of an immaterial business. The total costs associated with this plan were $6.1 million, and the Company expects to realize annual…

• Net revenue from AdaptHealth's Sleep Health segment increased by $39.0 million, or 11.0%, for the three months ended September 30, 2026 compared to the prior year period, primarily due to timing of the transition of patients related to a capitated revenue contract that was entered into in the third …

• Gain on deconsolidation of subsidiary. Represents a pre-tax gain associated with the deconsolidation of AdaptHealth's former wholly-owned eCommerce subsidiary as discussed in Note 1, General Information - Equity Method Investments.

• Interest expense, net. Interest expense, net for the three months ended September 30, 2026 and 2025 was $28.6 million and $25.4 million, respectively, an increase of $3.2 million. Interest expense related to AdaptHealth's debt increased by $0.1 million in 2026 compared to 2025 as a result of higher …

• Income Tax (Benefit) Expense. Income tax benefit and income tax expense for the three months ended September 30, 2026 and 2025 was $17.5 million and $6.5 million, respectively. Income tax expense on ordinary income decreased due to lower pre-tax income. For the three months ended September 30, 2026,…

相对上期删除的文字 · 来源:10-Q · 2026-08-04

• AdapthHealth. See Note 5, Held for Sale and Discontinued Operations, in the accompanying notes to the interim consolidated financial statements, for additional information regarding discontinued operations and assets and liabilities held for sale.

• In June 2026, management approved a plan aimed at reducing costs, streamlining operations, and optimizing resources, which included headcount reductions and the wind down of an immaterial business. The total costs associated with this plan is expected to be approximately $7.0 million, and the Compan…

• Net revenue from AdaptHealth's Sleep Health segment increased by $51.8 million, or 15.5%, for the three months ended June 30, 2026 compared to the prior year period, primarily due to a capitated revenue contract that was entered into in the third quarter of 2025. The increase was also attributable t…

• Loss on extinguishment of debt. The loss on extinguishment of debt for the three months ended June 30, 2026 relates to third-party fees and the write-off of unamortized deferred financing costs in connection with the refinancing of AdaptHealth's credit agreement. See Note 12, Debt, for additional di…

• Gain on sale of businesses. The gain for the three months ended June 30, 2026 relates to the receipt of a contingent payment from the disposition of a business that occurred in 2025. The gain for the three months ended June 30, 2025 relates to the disposition of two businesses within AdaptHealth's W…

相对上期新增的文字 · 来源:10-Q · 2026-11-03

• Reliance on relatively few suppliers for the majority of AdaptHealth's patient service equipment and supplies could adversely affect its ability to operate.

• AdaptHealth currently relies on a relatively small number of suppliers to provide it with the majority of its patient service equipment and supplies. Significant price increases, product recalls or other disruptions in the ability to obtain such equipment and supplies from existing suppliers, may fo…

• For example, in October 2026, AdaptHealth received notice from Medline Industries, LP (“Medline”) that Medline has initiated a voluntary field action involving the removal, repair, discontinuation, and market exit of all Medline Brand beds, including homecare beds, bariatric beds, and long-term-care…

相对上期删除的文字 · 来源:10-Q · 2026-08-04

• The pending sale of our Diabetes Health business may not be completed on the anticipated timeline, or at all.

• On July 19, 2026, we announced that we entered into an agreement to sell substantially all of the assets related to our Diabetes Health business (the “Divestiture”). We expect the closing of the Divestiture to occur in the first quarter of 2027, although there can be no assurances as to the timing o…

• If the pending sale of our Diabetes Health business is completed, we may not achieve the anticipated benefits of the transaction, and the completion of the Divestiture may expose us to new risks.

• Even if the Divestiture is completed, we may be unable to achieve the full strategic and financial anticipated benefits of the Divestiture, including the expected use of net proceeds to pay down debt and the deployment of capital toward higher growth and higher margin businesses in our core business…

• In addition, following the expected closing of the Divestiture, and subject to the limitations set forth in the transaction agreement, we agreed to indemnify the buyer for, among other things, breaches of representations, warranties, covenants and agreements and excluded assets and excluded liabilit…

相对上期删除的文字 · 来源:10-Q · 2026-08-04

• The information set forth in is included for the purpose of providing disclosure under “Item 2.03 — Creation of a Direct Financial Obligation” of Form 8-K.

• On July 27, 2026, the Company borrowed $325.0 million under the 2026 Delayed Draw Term Loan and the 2026 Credit Agreement to pay the redemption price of the 6.125% Senior Notes. Such notes were redeemed on August 3, 2026. The 2026 Delayed Draw Term Loan matures in April 2031. We will make quarterly …

• See Note 12, Debt, included in the accompanying notes to the interim consolidated financial statements for the three and six months ended June 30, 2026 and 2025 and Liquidity and Capital Resources section of this Quarterly Report for additional discussion.